An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)

Organon and Co1,104 enrolled

Overview

The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,104

Conditions

Hypercholesterolemia

Interventions

MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeksDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * High cholesterol Exclusion Criteria: * Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.

Outcomes

Primary Outcomes

Plasma LDL-C.

Secondary Outcomes

Plasma TG and HDL-C; proportion of patients achieving LDL-C targets; tolerability.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.